JAK Inhibitors in RA

MADRID – Findings from phase IIIB/IV ORAL Strategy study verify the safety and effectiveness of tofacitinib as a non–tumor necrosis factor inhibitor treatment option.

For difficult-to-treat RA, the better STRATEGY is to ADD-ON Tofacitinib to MTX, rather than to replace it.

Sure, Tofacitinib can be used alone (Oral SOLO), but it is only adequately effective in mild-to-moderate cases. If the RA is mild/moderate, why does one need to resort to expensive Tofacitinib in the first instance? Often, "MTX intolerance" is a relative luxury symptom.

Baricitinib Derailed by FDA Review

Eli Lilly and Co disclosed today that upon further discussions with the US Food and Drug Administration (FDA) there would be a delay in further regulatory decisions…

Filgotinib: Selective JAK1 inhibition shows promise in RA patients

The highly selective janus kinase 1 inhibitor filgotinib shows efficacy and has an encouraging safety profile in patients with rheumatoid arthritis and an inadequate response to methotrexate, say researchers who investigated the agent in two short…

Upadacitinib Effective in Rheumatoid Arthritis

AbbVie released the preliminary results of a rheumatoid arthritis trial wherein its Jak inhibitor, upadacitinib, was tested against placebo, and shown to be superior in…

AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis

NORTH CHICAGO, Ill., June 7, 2017 /PRNewswire/…
FDA sent similar drug for more clinical trials last spring

When thrombosis was an issue with Baricitinib holding up FDA approval, and 1 of 2 deaths with Upadacitinib is due to pulmonary embolism, it's more likely to be related than not.

No Comments Yet.

Leave a comment